Literature DB >> 8142642

Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia.

D F Claxton1, P Liu, H B Hsu, P Marlton, J Hester, F Collins, A B Deisseroth, J D Rowley, M J Siciliano.   

Abstract

Pericentric inversion of chromosome 16 [inv(16)(p13q22)] and the related t(16;16)(p13;q22) are seen in a subset of acute myelogenous leukemia (AML) phenotypically and prognostically differing from other cases. We have recently shown that inv(16) results in fusion of CBFB/PEBP2B, a gene encoded at 16q22 to MYH11, a smooth muscle myosin heavy chain gene encoded at 16p13. Chimeric transcripts consisting of upstream CBFB fused to downstream MYH11 coding sequences result from this fusion. In this study we have examined a series of 37 of these cases using reverse transcriptase-polymerase chain reaction (RT-PCR) to detect expression of a hybrid CBFB/MYH11 transcript. Chimeric cDNAs were detected in all but 1 of 37 leukemias with typical inv(16) or t(16;16). Such chimeric products were not seen in a case with inv(16)(p13q24) (ie, a variant q arm breakpoint) or any of 10 cases of AML without these chromosomal changes. Four different chimeric transcripts were found, representing differing fusion points within MYH11 spliced to position 495 of CBFB. Primer sets are described for efficient amplification of these different cDNA forms. Amplification of cDNA showed that all but 17 codons of the CBFB coding sequence are included in the abnormal transcripts. RT-PCR was shown to be highly sensitive and potentially useful for detection of leukemic cells during morphologic remission.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142642

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Detection of minimal residual disease in multiple myeloma and acute leukaemia.

Authors:  M H Bakkus; N Juge-Morineau; J E van der Werff ten Bosch
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

2.  A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.

Authors:  Ajeeta B Dash; Ifor R Williams; Jeffery L Kutok; Michael H Tomasson; Ema Anastasiadou; Kathleen Lindahl; Shaoguang Li; Richard A Van Etten; Julian Borrow; David Housman; Brian Druker; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  Acute myeloid leukemia with cryptic CBFB-MYH11 type D.

Authors:  Takashi Kobayashi; Motoshi Ichikawa; Yasuhiko Kamikubo; Mineo Kurokawa
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

4.  inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

Authors:  Sebastian Schwind; Colin G Edwards; Deedra Nicolet; Krzysztof Mrózek; Kati Maharry; Yue-Zhong Wu; Peter Paschka; Ann-Kathrin Eisfeld; Pia Hoellerbauer; Heiko Becker; Klaus H Metzeler; John Curfman; Jessica Kohlschmidt; Thomas W Prior; Jonathan E Kolitz; William Blum; Mark J Pettenati; Paola Dal Cin; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Stefano Volinia; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

5.  Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.

Authors:  Alireza Eghtedar; Gautam Borthakur; Farhad Ravandi; Elias Jabbour; Jorge Cortes; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2012-01-07       Impact factor: 10.047

6.  Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis.

Authors:  ShriHari S Kadkol; Annette Bruno; Carol Dodge; Valerie Lindgren; Farhad Ravandi
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

7.  The leukemic core binding factor beta-smooth muscle myosin heavy chain (CBF beta-SMMHC) chimeric protein requires both CBF beta and myosin heavy chain domains for transformation of NIH 3T3 cells.

Authors:  A Hajra; P P Liu; Q Wang; C A Kelley; T Stacy; R S Adelstein; N A Speck; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

8.  Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.

Authors:  John A Liu Yin; Lindsay Frost
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

9.  The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.

Authors:  C S Zent; C Mathieu; D F Claxton; D E Zhang; D G Tenen; J D Rowley; G Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

10.  Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: results from a multicenter validation study.

Authors:  C D Gocke; J Mason; L Brusca; W Laosinchai-Wolf; C Higgs; H Newell; A Masters; L Friar; J Karp; M Griffiths; Q Wei; E Labourier
Journal:  Blood Cancer J       Date:  2012-07-13       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.